Innovation Pharmaceuticals logo

Innovation Pharmaceuticals(OTC) IPIX

Market Cap$107.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-100%
5 Year-100%
1 Year-96%
1 Month-33%
$0.00
+0.00%
+0.00Today
Innovation Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-16
Innovation Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-10-09
1 month-33.33%USD 0.002026-09-16
3 month-93.33%USD 0.002026-07-17
Year to date-80%USD 0.002025-12-31
1 year-95.56%USD 0.002025-10-16
3 year-97.65%USD 0.012023-10-17
5 year-99.93%USD 0.282021-10-15
Since inception-99.83%USD 0.122007-05-04

Innovation Pharmaceuticals Financials at a Glance

Market Cap

$107.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

-$6.00K

Net Income (TTM)

-$2.65M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

85.52 (High)

Price

$0.00

Volume

114,800

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.05

Estimated Earnings Date

Dec 6, 2024

IPIX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Innovation Pharmaceuticals

Innovation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for various medical conditions. The company’s pipeline includes treatments for inflammatory diseases, cancer, dermatology, and infectious conditions, with a strong emphasis on innovative solutions.

Products and Services
  • Brilacidin: Targeting oral mucositis and inflammatory bowel disease
  • Kevetrin: An anti-cancer compound under investigation for ovarian cancer
  • Collaborative research agreements to enhance drug development
Growth Outlook
  • Strong pipeline with multiple drug candidates in various stages of development
  • Partnerships with established firms to accelerate research and development
  • Focus on addressing unmet medical needs in significant market segments
Financial Highlights
  • Recent quarterly revenue reported at $0, indicating ongoing development phase
  • Net income for Q1 2023 was -$880,000, reflecting investment in R&D
  • Cash and cash equivalents stood at $864,000 as of September 30, 2023
Innovation Pharmaceuticals Inc. operates in the biotechnology sector, emphasizing the development of innovative therapies. The company’s lead drug candidates, Brilacidin and Kevetrin, are positioned to address critical health challenges, including cancer and inflammatory diseases. The strategic partnerships with Alfasigma S.p.A. and Fox Chase Chemical Diversity Center, Inc. enhance the company’s research capabilities and market reach. Financially, the company is in a development phase, with no revenue reported in the latest quarter. The focus on research and development is evident in the significant net loss, which reflects the investment necessary to advance its drug candidates. The cash position, while limited, supports ongoing operations and development efforts. Overall, Innovation Pharmaceuticals Inc. presents a compelling opportunity for investors interested in the biotechnology sector, particularly those focused on innovative therapeutic solutions. The company’s commitment to addressing unmet medical needs and its strategic partnerships position it for potential growth in the evolving healthcare landscape.
AI Generated • Sep 28, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

Leo Ehrlich, CPA

Website

www.ipharminc.com

Headquarters

Wakefield, MA 01880, US

IPIX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-93.60%

Return on Capital

-112.55%

Return on Assets

-42.14%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

-2.71%

Stock Overview

Market Cap

$107.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

537.28M

Volume

114.80K

Avg. Volume

269.38K

Financials (TTM)

Gross Profit

-$375.00K

Operating Income

-$2.56M

EBITDA

-$2.19M

Operating Cash Flow

-$1.99M

Capital Expenditure

-$58.00K

Free Cash Flow

-$2.05M

Cash & ST Invst.

$864.00K

Total Debt

$238.00K

Innovation Pharmaceuticals Performance Analysis

Innovation Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 18,000N/A
20232023-06-30USD 0N/A
Innovation Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-12-31N/A
Q32023-03-31N/A
Q42023-06-30N/A
Q12023-09-30100.0%
Innovation Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -0.01N/A
20232023-06-30USD -0.01-55.0%
Innovation Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-12-3175.0%
Q32023-03-31-114.3%
Q42023-06-3013.3%
Q12023-09-30-30.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$88.00K

+5.4%

Gross Margin

0.00%

N/A

Market Cap

$107.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$26.88K

N/A

Employees

4

N/A

Net Income

-$880.00K

+38.4%

EBITDA

-$772.00K

+41.5%

Quarterly Fundamentals

Name
Q1 2024YOY CHG

Total Cash

$864.00K

-70.9%

Total Debt

$238.00K

-47.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$457.00K

-41.9%

Short Term Debt

$238.00K

-47.1%

Return on Assets

-42.14%

N/A

Return on Invested Capital

-1.25%

N/A

Free Cash Flow

-$679.00K

+14.6%

Operating Cash Flow

-$677.00K

+14.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MDINMedGen, Inc.
$0.00+0.00%
WSNAFWesana Health Holdings Inc.
$0.00+0.00%
LFCOFLift & Co. Corp.
$0.00+0.00%
NBIONascent Biotech, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$89.85-5.79%
NVDANvidia
$214.13-1.43%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
CCCCCC Intelligent Solutions
$7.61-0.26%

Questions About IPIX

What is the current price of Innovation Pharmaceuticals?

Innovation Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Innovation Pharmaceuticals?

Over the past 52 weeks, Innovation Pharmaceuticals has traded between $0.00 and $0.05.

How much debt does Innovation Pharmaceuticals have?

As of the most recent reporting period, Innovation Pharmaceuticals reported total debt of $725.00K.

How much cash does Innovation Pharmaceuticals have on hand?

Innovation Pharmaceuticals reported $1.52M in cash and cash equivalents in its most recent financial results.

What is Innovation Pharmaceuticals’s dividend yield?

Innovation Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services